title: Reappraisal of the clinical and biologic significance of myeloid-associated antigen expression in childhood acute lymphoblastic leukemia.
abstract: OBJECTIVE
  To reassess the clinical and biologic significance of myeloid-associated antigen expression in childhood acute lymphoblastic leukemia (ALL).
  
  
  METHODS
  We prospectively studied 334 newly diagnosed cases of this disease, using a comprehensive panel of antibodies that represented five myeloid cluster groups (CD13, CD14, CD15, CD33, and CD65). Blast cells were tested for ETV6 and MLL rearrangement using Southern blot analysis.
  
  
  RESULTS
  CD13 was expressed in 13.7% of cases, CD14 in 1%, CD15 in 6.6%, CD33 in 16%, and CD65 in 9.7%. Approximately one third of cases (31.4%) expressed one or more of these antigens (B-cell precursor, 31.9%; T-cell, 28.8%), while 10.5% expressed two or more (B-cell precursor, 11.3%; T-cell, 6.1%). Among the B-cell precursor leukemias, myeloid-associated antigen expression was significantly associated with a lack of hyperdiploidy and rearrangements of ETV6 or MLL gene. Most of the cases with MLL rearrangements (82%) expressed CD65, CD15, and CD33, either alone or in combination, whereas 48% of those with a rearranged ETV6 gene expressed CD13, CD33, or both. Myeloid-associated antigen expression did not correlate with event-free survival, whether the analysis was based on any of the five antigens in our panel or on the three more commonly tested antigens (CD13, CD33, and CD65). Importantly, this finding was not affected by exclusion of patients with ETV6 or MLL gene rearrangements.
  
  
  CONCLUSIONS
  Even though blast cell expression of myeloid-associated antigen expression shows significant associations with specific genetic abnormalities, it lacks prognostic value in childhood ALL.
authors.affiliation: Department of Hematology-Oncology, St Jude Children's Research Hospital, Memphis, TN 38105, USA. ching-hon.pui@stjude.org
authors.forename: C H
authors.initials: CH
authors.lastname: Pui
authors.forename: J E
authors.initials: JE
authors.lastname: Rubnitz
authors.forename: M L
authors.initials: ML
authors.lastname: Hancock
authors.forename: J R
authors.initials: JR
authors.lastname: Downing
authors.forename: S C
authors.initials: SC
authors.lastname: Raimondi
authors.forename: G K
authors.initials: GK
authors.lastname: Rivera
authors.forename: J T
authors.initials: JT
authors.lastname: Sandlund
authors.forename: R C
authors.initials: RC
authors.lastname: Ribeiro
authors.forename: D R
authors.initials: DR
authors.lastname: Head
authors.forename: M V
authors.initials: MV
authors.lastname: Relling
authors.forename: W E
authors.initials: WE
authors.lastname: Evans
authors.forename: F G
authors.initials: FG
authors.lastname: Behm
mesh_terms: D000293:Adolescent; D015703:Antigens, CD / Q000378:metabolism*; D000951:Antigens, Neoplasm / Q000378:metabolism*; D015139:Blotting, Southern; D001854:Bone Marrow Cells / Q000276:immunology*; D002648:Child; D002675:Child, Preschool; D018572:Disease-Free Survival; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D016130:Immunophenotyping; D007223:Infant; D008297:Male; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000276:immunology*; D011237:Predictive Value of Tests; D011446:Prospective Studies
chemical_list: D015703:Antigens, CD; D000951:Antigens, Neoplasm